Intuitive Surgical, Inc. $ISRG Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 8.7% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 4,123,290 shares of the medical equipment provider’s stock after selling 394,179 shares during the period. Bank of New York Mellon Corp’s holdings in Intuitive Surgical were worth $1,844,059,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC boosted its holdings in Intuitive Surgical by 24.9% in the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after purchasing an additional 731 shares during the last quarter. Sivia Capital Partners LLC raised its position in shares of Intuitive Surgical by 3.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock valued at $504,000 after buying an additional 34 shares during the period. Kathmere Capital Management LLC acquired a new position in Intuitive Surgical in the second quarter valued at approximately $203,000. Avior Wealth Management LLC lifted its holdings in Intuitive Surgical by 29.0% in the second quarter. Avior Wealth Management LLC now owns 1,700 shares of the medical equipment provider’s stock valued at $924,000 after acquiring an additional 382 shares during the last quarter. Finally, Independence Bank of Kentucky grew its position in Intuitive Surgical by 18.8% in the second quarter. Independence Bank of Kentucky now owns 1,133 shares of the medical equipment provider’s stock worth $616,000 after acquiring an additional 179 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $525.04 on Wednesday. The firm has a market cap of $188.21 billion, a price-to-earnings ratio of 66.55, a PEG ratio of 4.12 and a beta of 1.67. The firm has a 50 day simple moving average of $561.53 and a 200-day simple moving average of $511.67. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $609.08.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The company had revenue of $2.87 billion for the quarter, compared to analyst estimates of $2.72 billion. During the same period in the prior year, the business earned $2.21 EPS. The firm’s quarterly revenue was up 18.8% on a year-over-year basis. Equities analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other Intuitive Surgical news, SVP Mark Brosius sold 464 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $548.49, for a total value of $254,499.36. Following the sale, the senior vice president owned 131 shares of the company’s stock, valued at $71,852.19. This trade represents a 77.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Myriam Curet sold 104 shares of the business’s stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $559.90, for a total value of $58,229.60. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 48,027 shares of company stock valued at $27,402,696. 0.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on ISRG shares. Mizuho set a $575.00 price target on Intuitive Surgical in a research note on Wednesday, October 22nd. Truist Financial boosted their price objective on shares of Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Robert W. Baird lowered their target price on shares of Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Citigroup reiterated a “neutral” rating and set a $590.00 price target (down from $635.00) on shares of Intuitive Surgical in a research report on Friday. Finally, Jefferies Financial Group upped their price objective on shares of Intuitive Surgical from $550.00 to $560.00 and gave the stock a “hold” rating in a report on Wednesday, October 22nd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $620.41.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: TD Cowen initiated coverage with a Buy and a $660 target, citing the da Vinci 5 rollout and secular procedure growth as catalysts that could drive multi-year revenue and margin upside. TD Cowen initiates coverage
• Positive Sentiment: TD Cowen / TipRanks coverage note expands on the same thesis, highlighting da Vinci 5 rollout execution and secular procedure growth as underpinning a $660 target. TipRanks: TD Cowen Buy Rating
• Positive Sentiment: The FDA granted 510(k) clearance for the da Vinci 5 in select cardiac procedures, expanding the platform into more minimally invasive heart surgeries — a direct product/regulatory win that can support procedure growth and long-term consumable revenue. da Vinci 5 FDA clearance
• Positive Sentiment: HSBC raised its price target to $653 and maintained a Buy, reinforcing bullish analyst sentiment and implying meaningful upside from current levels. HSBC raises PT to $653
• Positive Sentiment: Barclays reiterated its Buy rating, another vote of confidence from the sell-side that supports investor sentiment. Barclays remains Buy
• Positive Sentiment: American Banking News reports a raised price target to $615, adding to the cluster of higher analyst targets that can support upside expectations. Price target raised to $615
• Neutral Sentiment: Interest in ISRG is high among retail/institutional investors (searches up), which can increase short-term volatility but does not by itself change fundamentals. Investors heavily search ISRG
• Negative Sentiment: Zacks highlights rising competitive pressure in China — slower tenders, local favoritism and pricing pressure — which could weigh on growth and margins in a key market if trends accelerate. China competition headwinds
• Negative Sentiment: Robert W. Baird trimmed its price target to $645 — a modest downgrade that could temper upside expectations even though the target remains above current levels. Baird cuts PT to $645

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.